Last reviewed · How we verify

RiaSTAP — Competitive Intelligence Brief

RiaSTAP (RiaSTAP) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrinogen concentrate. Area: Hematology.

marketed Fibrinogen concentrate Fibrinogen (Factor I) Hematology Small molecule Live · refreshed every 30 min

Target snapshot

RiaSTAP (RiaSTAP) — Weill Medical College of Cornell University. RiaSTAP is a fibrinogen concentrate that replaces or supplements fibrinogen to restore clotting ability in patients with fibrinogen deficiency.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
RiaSTAP TARGET RiaSTAP Weill Medical College of Cornell University marketed Fibrinogen concentrate Fibrinogen (Factor I)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrinogen concentrate class)

  1. Weill Medical College of Cornell University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RiaSTAP — Competitive Intelligence Brief. https://druglandscape.com/ci/riastap. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: